CAMPTO (irinotecan): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

CAMPTO 20 mg/ml, concentrate for solution for infusion (100mg & 300mg presentation)

CAMPTO is indicated for the treatment of patients with advanced colorectal cancer:

• in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,

• as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

CAMPTO in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing KRAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy (please see 5.1).

CAMPTO in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

CAMPTO in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.

Campto 20mg/ml concentrate for solution for infusion (40mg presentation)

CAMPTO is indicated for the treatment of patients with advanced colorectal cancer:

• in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,

• as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

CAMPTO in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing KRAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy (please see 5.1).

CAMPTO in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

CAMPTO in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.


Route of administration: Injectable
Molecule: irinotecan

Patients' opinions on CAMPTO

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

Fact sheet

Colorectal cancer

See the fact sheet